

## 1 **Abstract**

2 **Background:** The Barrow Neurological Institute (BNI) score, measuring maximal thickness of  
3 aneurysmal subarachnoid hemorrhage (aSAH), has previously shown to predict symptomatic  
4 cerebral vasospasms (CVS), delayed cerebral ischemia (DCI) and functional outcome.

5 **Objective:** We aim to validate the BNI score for prediction of above-mentioned variables and  
6 cerebral infarct and evaluate its improvement by integrating further variables which are  
7 available within the first 24 hours after hemorrhage.

8 **Patients and Methods:** We included patients from a single center. The BNI score for prediction  
9 of CVS, DCI, infarct and functional outcome was validated in our cohort using measurements  
10 of calibration and discrimination (area under the receiver operating characteristic curve  
11 [AUC]). We improved it by adding additional variables, creating a novel risk score (measured  
12 by dichotomized Glasgow Outcome Scale) and validated it in a small independent cohort.

13 **Results:** Of 646 patients, 41.5% developed symptomatic CVS, 22.9% DCI, 23.5% cerebral  
14 infarct, and 29% had an unfavorable outcome. The BNI score was associated with all outcome  
15 measurements. We improved functional outcome prediction accuracy by including age, BNI  
16 score, WFNS, rebleeding, clipping, and hydrocephalus (AUC 0.84, 95%CI 0.8-0.87). Based on  
17 this model we created a risk score (HATCH - Hemorrhage, Age, Treatment, Clinical State,  
18 Hydrocephalus), ranging\_0-13 points. We validated it in a small independent\_cohort. The  
19 validated score demonstrated very good discriminative ability (AUC\_0.84 [95%CI 0.72-0.96]).

20 **Conclusion:** We developed the HATCH-score, which is a moderate predictor of DCI, but  
21 excellent predictor of functional outcome at 1 year after aSAH.

22

## 23 **Running title**

24 Validation of BNI score: creating the HATCH score

25

## 26 **Keywords**

27 Subarachnoid hemorrhage; barrow neurological institute grade; delayed cerebral ischemia;  
28 outcome; prediction

29

## 30 INTRODUCTION

31 Subarachnoid hemorrhage is a rare form of stroke comprising 5% of all strokes with an annual  
32 incidence of 9/100,000<sup>1</sup>. In 85% the underlying cause is a ruptured intracranial aneurysm  
33 causing aneurysmal subarachnoid hemorrhage (aSAH)<sup>2</sup>. It has a 6-month case fatality of up to  
34 60%, however more recent studies show a decreasing trend of 0.9% per year over the last  
35 decades<sup>2-4</sup>. Overall outcome is notably influenced by aSAH related complications such as  
36 recurrent hemorrhage, hydrocephalus (HCP), cerebral vasospasm (CVS), and delayed cerebral  
37 ischemia (DCI)<sup>1</sup>. Despite significant advances in acute care and surgical and endovascular  
38 treatment over the last 30 years, outcome after aSAH still remains poor<sup>2,5</sup>. Approximately 30%  
39 of patients develop DCI within 3-12 days after the initial hemorrhage which remains one of the  
40 leading causes for poor outcome<sup>6-8</sup>. Studies showed that the amount of blood on initial CT scan  
41 is associated with the development of CVS and DCI<sup>1,2,9</sup>. Cerebral infarct might be an even better  
42 outcome predictor than DCI<sup>10,11</sup>. Several prediction models are available to identify patients  
43 who are at risk for CVS and DCI<sup>12-17</sup>. A simple prediction tool is the Barrow Neurological  
44 Institute (BNI) score<sup>18</sup>. It assesses the point of maximal thickness of subarachnoid blood  
45 particularly across the cistern or fissure allocating patients into five groups<sup>18</sup>. It demonstrates a  
46 proportional increase in CVS risk and has proven to be superior to the more widely used Fisher  
47 scale in predicting symptomatic CVS<sup>9,18</sup>. Moreover, the BNI score is also a promising tool in  
48 predicting DCI and functional outcome after aSAH. A previous study has additionally  
49 demonstrated that outcome prediction by the BNI score can further be improved by adding  
50 WFNS score and age<sup>16</sup>. This might allow early identification of patients at risk for DCI and  
51 therefore help in selecting patients who might profit from more intensive monitoring or  
52 prophylactic treatment of DCI. Improved functional outcome prediction models will guide  
53 physicians towards more individualized decision making.

54 In this study we aim to externally validate the original BNI score for CVS, DCI and functional  
55 outcome prediction, followed by validation of the extended BNI score as published by Neidert  
56 et al. <sup>16,18</sup>. We additionally evaluate the BNI score in predicting cerebral infarct. Finally, we  
57 will investigate the improvement of functional outcome prediction by adding relevant  
58 parameters available on admission to the BNI score to ultimately create a novel risk score. We  
59 will then externally validate it in a separate collected cohort.

60

## 61 PATIENTS AND METHODS

### 62 Study population

63 We used the prospectively collected aSAH database of the Neurosurgical Department of the  
64 University Hospital Zurich, Switzerland, collected between January 2005 and December 2016.  
65 The database consisted of 721 patients. Demographic, radiological and clinical outcome data  
66 were collected using standardized forms and entered into the database of the Department of  
67 Neurosurgery. Patients without available CT on admission and those who died before day 4  
68 were excluded from the analysis. For outcome prediction we only included patients with  
69 available GOS on follow-up. Follow-up GOS was assessed in our outpatient clinic. All patients  
70 were treated by the standard of care of our department, a highly specialized and tertiary referral  
71 center for patients with cerebrovascular diseases, which follows international guidelines at the  
72 given time<sup>1,19,20</sup>. Our institution does have protocols in place for the escalation of treatment and  
73 uses a 3-bolt system routinely in all patients with aSAH requiring sedation and intubation<sup>21</sup>.  
74 The cohort for validation of the created risk score is an independent, prospectively collected  
75 cohort of 51 consecutive patients treated in the same unit between 01/2017 and 05/2018 with  
76 available functional outcome at 1 year.

### 77 **Definition of variables**

78 Hypertension, hypercholesterolemia, and diabetes mellitus were all diagnosed if medical  
79 records or patients reported these diagnoses or if advice, lifestyle changes or drug treatment had  
80 been previously been provided. We measured clinical severity on admission using two grading  
81 systems: WFNS and Hunt and Hess<sup>22,23</sup>. Hyperglycemia on admission is defined as blood  
82 glucose reaching values >8mmol/l.

83 We defined CVS as radiologically confirmed intracranial arterial narrowing (vasoconstriction)  
84 on digital subtraction angiography, CT angiography and/or MR angiography<sup>24</sup>. We defined DCI  
85 as a delayed decrease of the Glasgow Coma Scale (GCS) of at least 2 points and/or new focal  
86 neurological deficit without other underlying cause<sup>25</sup>. Delayed cerebral infarct is defined as  
87 radiologically proven new infarcts, not occurring within 48 hours of a surgical intervention,  
88 including aneurysm coiling or clipping<sup>15</sup>. Rebleeding is defined as a recurrent bleed from the  
89 aneurysm. Hydrocephalus is defined as an enlargement of the ventricular system requiring  
90 intervention<sup>26</sup>. We used the Glasgow Outcome Score (GOS) at 1 year to assess functional  
91 outcome. We dichotomized the GOS into unfavorable (1-3) and favorable (4-5) outcome,  
92 respectively<sup>27-32</sup>.

### 93 **CT grading**

94 An independent neuroradiologist rated all CT scans on admission to determine the maximal  
95 thickness of subarachnoid blood (diameter of blood) particularly across the cistern or fissure  
96 allocating patients to Fisher and BNI score, as well later CT scans in order to detect delayed

97 cerebral infarcts according to standard protocols<sup>9,18</sup>. Scans were reviewed by a consultant  
98 neuroradiologist. Both were blinded to the patient's clinical state.

## 99 **Statistical Analysis**

### 100 *Statistical analysis*

101 Categorical variables are presented as count and percentage, continuous variables as mean with  
102 standard deviation (SD). We compared groups using the Chi-square or Fisher's exact test for  
103 our binary outcome variables.

104 For the multivariate models for CVS and DCI we adjusted for the pre-specified variables age,  
105 sex, hypertension, smoker and BNI score based on previous studies, which are readily available  
106 on admission. For infarct we additionally pre-specified WFNS and DCI.

### 107 *Validation and performance in our cohort:*

108 We validated the BNI score for CVS prediction as originally presented<sup>18</sup>. We then evaluated  
109 the performance of the BNI score for DCI, infarct and functional outcome prediction in our  
110 cohort (without restricting to just Fisher 3 patients, as previously published)<sup>16</sup>. We calculated  
111 odds ratios (OR) for each grade of BNI score relative to the highest grade. As a final step, we  
112 additionally validated the prediction of the extended BNI score of DCI and unfavorable  
113 functional outcome as per Neidert et al<sup>16</sup>.

### 114 *Extension and risk score creation for functional outcome:*

115 To develop a new score to predict unfavorable functional outcome, defined as GOS 1-3, we  
116 fitted a multivariate regression model based on variables that were statistically significant at  
117 the 5% level in univariate analyses, as well as with the pre-specified variables age  
118 (dichotomized into younger or older than 60 years), sex, smoker, hypertension and BNI based  
119 on previous studies. We quantified discrimination by the area under the receiver-operating  
120 characteristic curve (AUC)<sup>33</sup>: an AUC of 0.5 indicates no, of >0.7 acceptable, of >0.8 good, of  
121 >0.9 excellent, and of 1 perfect discriminative abilities.

### 122 *Validation:*

123 The derived model was validated internally using bootstrap validation (with 200 bootstrap  
124 samples) and measures of predictive performance assessing calibration (calibration slope) and  
125 discrimination (measured by the AUC) were calculated<sup>34</sup>. Briefly, the calibration slope is a  
126 regression-based method to assess the agreement between observed and predicted values, with  
127 a calibration slope of 1 suggesting good calibration. We then validated the risk score in an  
128 independent cohort collected at a different time period at the same institution. To measure the  
129 performance of the new developed score, we used the Hosmer-Lemeshow test for calibration  
130 and AUC for discrimination<sup>34</sup>.

131 Statistical analysis was performed using STATA 15 (StataCorp. 2011. *Stata Statistical*  
132 *Software: Release 15*. College Station, TX: StataCorp LP).

### 133 *Ethical approval*

134 The study was approved by the local ethics committee of Zurich, Switzerland. As this dataset  
135 was part of a registry approved by the local ethics committee no patient consent form was  
136 required.

137

## 138 **RESULTS**

139 Of 721 patients, 646 had all variables available except for treatment (clipping and coiling), as  
140 5 patients were neither clipped nor coiled, and unfavorable outcome. Of 646 included patients,  
141 functional outcome on follow-up was available for 504 (78%) patients; 142 patients were  
142 therefore not included into the functional outcome analysis (Supplemental Figure 1). See Table  
143 1 for baseline characteristics: mean age was 55.4 years (SD 13, range 14-88) and 432 (66.9%)  
144 were female. Overall, 268 patients developed CVS (41.5%), 148 patients developed DCI  
145 (22.9%), 152 (23.5%) delayed cerebral infarction and 146 (29.0%) had an unfavorable outcome  
146 at 1 year. The results of univariable analyses for each outcome can be seen in supplementary  
147 Tables 1-4.

### 148 **Outcome prediction by the original BNI score**

#### 149 *Prediction of CVS*

150 Compared to the original BNI paper by Wilson et al. we had a higher rate of high BNI scores  
151 indicating a higher rate of severe bleeds (Table 1)<sup>18</sup>. Overall, the BNI score was associated with  
152 CVS (p=0.003). With BNI 5 as a reference group, all other BNI scores had a lower likelihood  
153 in developing symptomatic CVS (Table 2). The AUC was 0.58 (95% CI 0.54-0.62), indicating  
154 poor discriminative ability in predicting CVS (Figure 1).

155 The multivariable model to predict CVS was fitted with the predefined variables age, sex,  
156 hypertension, BNI score, and smoker (Supplementary Table 5). It had an overall p-value of  
157 <0.001 and showed low discriminative ability measured by an AUC of 0.64 (95% CI 0.60-0.69,  
158 Figure 2A).

#### 159 *Prediction of DCI*

160 Like for CVS, DCI had higher a higher rate of BNI score 4 and 5, whereas again patients without  
161 DCI had a higher rate of BNI score 1-3 (overall p-value=0.04, Table 2). The BNI score was  
162 associated with DCI in the univariable analysis (overall p-value=0.04, Table 2 and  
163 Supplementary Table 2). The multivariate model to predict DCI was again fitted with the  
164 predefined variables age, sex, hypertension, BNI score, and smoker and had an overall p-value

165 of 0.004 (Supplementary Table 6). The model showed low discriminative ability measured by  
166 an AUC of 0.63 (95% CI 0.58-0.68, Figure 2B).

### 167 *Prediction of infarction*

168 Patients who developed cerebral infarcts had a higher rate of BNI score 4 and 5, whereas  
169 patients without cerebral infarcts a higher rate of BNI score 2 and 3 (overall p-value=0.03,  
170 Table 2). The multivariate model for infarction prediction was adjusted with the predefined  
171 variables. The model fit did not significantly change when removing sex and smoker and  
172 therefore these variables were not included in the final model (Supplementary Table 7). This  
173 final model had an overall p-value of <0.001 and a strong discriminative ability with an AUC  
174 of 0.84 (95% CI 0.81-0.88, Figure 2C).

### 175 *Prediction of unfavorable outcome measured by the GOS at 1 year*

176 The BNI score is significantly associated with functional outcome after aSAH (overall p-  
177 value<0.001, Table 2. For the multivariate regression we only included variables which were  
178 available within the first 24 hours. We adjusted the model with WNFS, clipping, hydrocephalus  
179 and rebleeding in addition to the predefined variables. The model demonstrated good  
180 discriminative ability with an AUC of 0.84 (95% CI 0.81-0.88).

### 181 **Validation of BNI score for DCI and functional outcome sub-stratifying by Fisher 3** 182 **according to Neidert et al.<sup>16</sup>**

183 The vast majority of patients (96.1%) had a Fisher score of 3. When evaluating DCI prediction  
184 sub-stratified by Fisher 3 (patients with a Fisher score of 3), there was a trend of decreasing  
185 likelihood of DCI with decreasing BNI score (Table 3). The AUC was 0.57, (95% CI 0.52-  
186 0.62) indicating poor discriminative abilities (Figure 3A). Supplemental Figure 2 demonstrates  
187 the GOS distribution by BNI score.

188 When evaluating unfavorable outcome sub-stratified by Fisher 3, the BNI score was associated  
189 with unfavorable outcome (overall p-value <0.001). This association was linear with declining  
190 BNI score (Table 3). The AUC for the sub-stratified BNI score association analysis was 0.64  
191 (95%CI 0.59-0.7, Figure 3B). Next, we validated the score proposed by Neidert et al. by adding  
192 WFNS and age to BNI score. This led to a slight improvement in the discriminative abilities of  
193 predicting unfavorable outcome by increasing the AUC 0.79 (95% CI 0.74-0.83, Figure 3C).

### 194 **Creation of risk score for functional outcome prediction and independent validation**

195 As ultimately the prediction of the three other outcome variables results in the prediction of  
196 functional outcome and due to the promising results above, we created a point-based risk score  
197 for GOS prediction at 1 year due to the importance of predicting functional outcome. Since sex,  
198 smoker and hypertension did not significantly predict unfavorable outcome and their exclusion

199 did not significantly change the model (data not shown) or its discriminative ability (AUC 0.84  
200 (95% CI 0.8-0.88, Figure 4). Thus, the final model contained following variables: age, BNI  
201 score, WFNS, clipping, hydrocephalus, and rebleeding (Table 4)

202 From this we created a point-based risk score for GOS prediction at 1 year, the HATCH score,  
203 which stands for: Hemorrhage (BNI score and rebleeding), Age ( $\leq 60$  versus  $>60$  years of age),  
204 Treatment (coiling versus clipping), clinical state measured by the WFNS and Hydrocephalus.  
205 We assigned points to each of the six independent predictors based on the strength of  
206 association (regression coefficients) with the outcome. A higher score is associated with an  
207 increased risk of unfavorable outcome with the maximum score of 13 points yielding a risk of  
208 98.3% (Table 5). See supplemental Figure 3 demonstrating HATCH vs risk of unfavorable  
209 outcome.

210 In a final step we validated the risk score in a separate cohort of 51 patients from the same  
211 department. Due to the small size of the validation cohort we combined the score into four  
212 categories: 0-4, 5-6, 7-8 and 9-12. The discriminative ability for unfavourable outcome  
213 prediction at 1 year, measured by the AUC, was 0.84 (95% CI 0.72-0.96, Figure 5) indicating  
214 good discriminative ability. Calibration, as assessed by the Hosmer-Lemeshow test, however,  
215 was poor ( $p < 0.001$ ). In particular, there was poor agreement between the observed and  
216 expected event rates for groups 5-6, although performance in the other groups was acceptable.

217

## 218 **DISCUSSION**

219 We successfully validated the original BNI score for the prediction of CVS, DCI, cerebral  
220 infarct and unfavorable outcome as well as the BNI score sub-stratified by Fisher 3 score,  
221 as proposed by Neidert et al. and their extended BNI score. We then created a new risk score,  
222 the HATCH score, for unfavorable outcome prediction based on variables present within 24  
223 hours of admission – BNI score and rebleeding, age, treatment, clinical state and hydrocephalus  
224 - and validated it in a separate cohort showing good discriminative ability with an AUC of 0.84.  
225 Our study has several strengths. The included sample size is relatively large and comes from a  
226 prospectively collected database in a tertiary referral center. The definition of variables has  
227 been made according to previous guidelines and consensus<sup>25</sup>. The HATCH score only uses  
228 variables which are available within 24 hours of admission making it applicable in the very  
229 early stages of this disease. It also offers the opportunity of a further extension of the score  
230 during the course of the disease.

231 Our study also has limitations: despite the cohort being collection prospectively, the analysis  
232 was conducted retrospectively. A prospective approach is preferred as a focus on the outcome

233 variables of interest can particularly reduce missingness. Multiple imputation would be a great  
234 tool to overcome this problem, however, it is not a generally advised method for imputation of  
235 outcome variables. Also, a direct comparison to the previously published validation by Neidert  
236 et al., including their extended score, is limited: they used the modified Ranking Scale (mRS)  
237 as opposed to the GOS for functional outcome measurement. Additionally, 22% were lost to  
238 follow-up and therefore had no functional outcome available. Another important limitation is  
239 that although discriminative ability of the HATCH score was good in the independent validation  
240 cohort, calibration was poor, most likely due to the small sample size. The validation cohort of  
241 51 individuals can only be considered exploratory due to the small number of patients. Finally,  
242 the recruitment period of 11 years could lead to bias due to potentially improved outcome over  
243 time. We did investigate the differences of mortality as well as unfavorable outcome over the  
244 years and they did not differ significantly (data not shown).

245 Our findings are consistent with previous findings<sup>10,16,35</sup>. The BNI score significantly and  
246 successfully predicts CVS, DCI, cerebral infarct and functional outcome<sup>18,25</sup>. Based on a  
247 previous study demonstrating the potential of BNI score being included in a simple risk score  
248 we created the HATCH score<sup>16</sup>. Compared to the extended BNI score by Neidert et al.,  
249 however, we created a risk score including all Fisher grades. Key feature of the HATCH score  
250 is the focus on only variables present within 24 hours of admission. The HATCH score  
251 demonstrates good discriminative ability (AUC of 0.84), accurately discriminating patients into  
252 high or low risk for unfavorable functional outcome. Despite the small size of the independent  
253 validation cohort, the score demonstrated good discriminative ability measured by an AUC of  
254 0.84.

255 Despite a large enough sample size to achieve adequate power, the BNI score was only a  
256 moderate predictor of DCI. However, it is indeed a strong and statistically significant predictor  
257 of functional outcome. Further factors such as age, WFNS, rebleeding, clipping, and  
258 hydrocephalus easily improve its predictive ability. In our cohort, patients who were clipped  
259 had a lower chance of good outcome. Although we cannot conclusively explain this finding,  
260 this might be either due to the invasiveness of the surgery or a potentially higher-grade  
261 hemorrhage. Many scoring systems already exist with the aim of predicting different  
262 complications as well as functional outcome after aSAH<sup>5,9,16-18,36-42</sup>. The advantage of the  
263 HATCH score lies in its composition by radiological as well as clinical and interventional  
264 variables which are available right on admission or within 24h. Compared to other scoring  
265 systems this enables clinicians to predict functional outcome very early during the course of the  
266 disease which is especially important in guiding families and carers in decision making

267 processes. Most importantly, all of the included variables will be available in respective centers  
268 and do not need any deviation from the standard of care. It is further strengthened by the fact  
269 that it was successfully externally validated and also externally validated the BNI and extended  
270 BNI score. This indicates that the HATCH score can be generalized. The extended BNI score  
271 described by Neidert et al. demonstrates an improvement in predicting functional outcome and  
272 a good discriminative ability also in our cohort. However, this could be influenced by the fact  
273 that some of our patients overlapped with the cohort used by Neidert et al.<sup>43</sup>. Although only  
274 some patients overlap, these two cohorts are not two fully independent cohorts.

275 A previous study noted that clinical parameters are better in predicting outcome and  
276 radiological parameters do not improve their prediction abilities<sup>10</sup>. In our cohort, the BNI score  
277 was equally effective in predicting CVS and DCI, but the WFNS was better in predicting  
278 cerebral infarct and functional outcome substantiating these previous findings.

279

## 280 **CONCLUSION**

281 The newly created and easy-applicable HATCH score is a moderate predictor of DCI, but  
282 excellent predictor of functional outcome at 1 year after aSAH and demonstrating good  
283 discriminative abilities. Due to only a small sample size in the independent validation cohort,  
284 this score requires validation in a larger independent cohort to confirm our results.

285 **References**

286

- 287 1. Steiner T, Juvela S, Unterberg A, Jung C, Forsting M, Rinkel G. European stroke  
288 organization guidelines for the management of intracranial aneurysms and  
289 subarachnoid haemorrhage. *Cerebrovascular diseases*. 2013;35(2):93-112.
- 290 2. van Gijn J, Kerr RS, Rinkel GJ. Subarachnoid haemorrhage. *Lancet*.  
291 2007;369(9558):306-318.
- 292 3. Lovelock CE, Rinkel GJ, Rothwell PM. Time trends in outcome of subarachnoid  
293 hemorrhage: Population-based study and systematic review. *Neurology*.  
294 2010;74(19):1494-1501.
- 295 4. Mackey J, Khoury JC, Alwell K, et al. Stable incidence but declining case-fatality  
296 rates of subarachnoid hemorrhage in a population. *Neurology*. 2016;87(21):2192-  
297 2197.
- 298 5. Harrod CG, Bendok BR, Batjer HH. Prediction of cerebral vasospasm in patients  
299 presenting with aneurysmal subarachnoid hemorrhage: a review. *Neurosurgery*.  
300 2005;56(4):633-654; discussion 633-654.
- 301 6. Hijdra A, Van Gijn J, Stefanko S, Van Dongen KJ, Vermeulen M, Van Crevel H.  
302 Delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage:  
303 clinicoanatomic correlations. *Neurology*. 1986;36(3):329-333.
- 304 7. Jabbarli R, Glasker S, Weber J, Taschner C, Olschewski M, Van Velthoven V.  
305 Predictors of Severity of Cerebral Vasospasm caused by Aneurysmal Subarachnoid  
306 Hemorrhage. *Journal of stroke and cerebrovascular diseases : the official journal of*  
307 *National Stroke Association*. 2013.
- 308 8. Roos YB, de Haan RJ, Beenen LF, Groen RJ, Albrecht KW, Vermeulen M.  
309 Complications and outcome in patients with aneurysmal subarachnoid  
310 haemorrhage: a prospective hospital based cohort study in the Netherlands.  
311 *Journal of neurology, neurosurgery, and psychiatry*. 2000;68(3):337-341.
- 312 9. Fisher CM, Kistler JP, Davis JM. Relation of cerebral vasospasm to subarachnoid  
313 hemorrhage visualized by computerized tomographic scanning. *Neurosurgery*.  
314 1980;6(1):1-9.
- 315 10. Dengler NF, Sommerfeld J, Diesing D, Vajkoczy P, Wolf S. Prediction of cerebral  
316 infarction and patient outcome in aneurysmal subarachnoid hemorrhage:  
317 comparison of new and established radiographic, clinical and combined scores.  
318 *European journal of neurology*. 2018;25(1):111-119.
- 319 11. Vilkki JS, Juvela S, Siironen J, Ilvonen T, Varis J, Porras M. Relationship of local  
320 infarctions to cognitive and psychosocial impairments after aneurysmal  
321 subarachnoid hemorrhage. *Neurosurgery*. 2004;55(4):790-802; discussion 802-  
322 793.
- 323 12. Etminan N, Beseoglu K, Heiroth HJ, Turowski B, Steiger HJ, Hanggi D. Early  
324 perfusion computerized tomography imaging as a radiographic surrogate for  
325 delayed cerebral ischemia and functional outcome after subarachnoid  
326 hemorrhage. *Stroke; a journal of cerebral circulation*. 2013;44(5):1260-1266.
- 327 13. Jabbarli R, Reinhard M, Roelz R, et al. Early identification of individuals at high risk  
328 for cerebral infarction after aneurysmal subarachnoid hemorrhage: the  
329 BEHAVIOR score. *Journal of cerebral blood flow and metabolism : official journal of*  
330 *the International Society of Cerebral Blood Flow and Metabolism*.  
331 2015;35(10):1587-1592.

- 332 14. de Oliveira Manoel AL, Jaja BN, Germans MR, et al. The VASOGRADE: A Simple  
333 Grading Scale for Prediction of Delayed Cerebral Ischemia After Subarachnoid  
334 Hemorrhage. *Stroke; a journal of cerebral circulation*. 2015;46(7):1826-1831.
- 335 15. de Rooij NK, Greving JP, Rinkel GJ, Frijns CJ. Early prediction of delayed cerebral  
336 ischemia after subarachnoid hemorrhage: development and validation of a  
337 practical risk chart. *Stroke; a journal of cerebral circulation*. 2013;44(5):1288-  
338 1294.
- 339 16. Neidert MC, Maldaner N, Stienen MN, et al. The Barrow Neurological Institute  
340 Grading Scale as a Predictor for Delayed Cerebral Ischemia and Outcome After  
341 Aneurysmal Subarachnoid Hemorrhage: Data From a Nationwide Patient Registry  
342 (Swiss SOS). *Neurosurgery*. 2018.
- 343 17. Frontera JA, Claassen J, Schmidt JM, et al. Prediction of symptomatic vasospasm  
344 after subarachnoid hemorrhage: the modified fisher scale. *Neurosurgery*.  
345 2006;59(1):21-27; discussion 21-27.
- 346 18. Wilson DA, Nakaji P, Abla AA, et al. A simple and quantitative method to predict  
347 symptomatic vasospasm after subarachnoid hemorrhage based on computed  
348 tomography: beyond the Fisher scale. *Neurosurgery*. 2012;71(4):869-875.
- 349 19. Connolly ES, Jr., Rabinstein AA, Carhuapoma JR, et al. Guidelines for the  
350 management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare  
351 professionals from the American Heart Association/american Stroke Association.  
352 *Stroke; a journal of cerebral circulation*. 2012;43(6):1711-1737.
- 353 20. Dinger MN, Bleck TP, Claude Hemphill J, 3rd, et al. Critical care management of  
354 patients following aneurysmal subarachnoid hemorrhage: recommendations from  
355 the Neurocritical Care Society's Multidisciplinary Consensus Conference.  
356 *Neurocritical care*. 2011;15(2):211-240.
- 357 21. Bailey RL, Quattrone F, Curtin C, et al. The Safety of Multimodality Monitoring  
358 Using a Triple-Lumen Bolt in Severe Acute Brain Injury. *World neurosurgery*.  
359 2019;130:e62-e67.
- 360 22. Hunt WE, Hess RM. Surgical risk as related to time of intervention in the repair of  
361 intracranial aneurysms. *Journal of neurosurgery*. 1968;28(1):14-20.
- 362 23. Teasdale GM, Drake CG, Hunt W, et al. A universal subarachnoid hemorrhage scale:  
363 report of a committee of the World Federation of Neurosurgical Societies. *Journal*  
364 *of neurology, neurosurgery, and psychiatry*. 1988;51(11):1457.
- 365 24. Vergouwen MD, Participants in the International Multi-Disciplinary Consensus  
366 Conference on the Critical Care Management of Subarachnoid H. Vasospasm versus  
367 delayed cerebral ischemia as an outcome event in clinical trials and observational  
368 studies. *Neurocritical care*. 2011;15(2):308-311.
- 369 25. Vergouwen MD, Vermeulen M, van Gijn J, et al. Definition of delayed cerebral  
370 ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in  
371 clinical trials and observational studies: proposal of a multidisciplinary research  
372 group. *Stroke; a journal of cerebral circulation*. 2010;41(10):2391-2395.
- 373 26. Reikate HL. The definition and classification of hydrocephalus: a personal  
374 recommendation to stimulate debate. *Cerebrospinal Fluid Res*. 2008;5:2.
- 375 27. Lagares A, Gomez PA, Lobato RD, Alen JF, Alday R, Campollo J. Prognostic factors  
376 on hospital admission after spontaneous subarachnoid haemorrhage. *Acta*  
377 *neurochirurgica*. 2001;143(7):665-672.
- 378 28. Rosen DS, Macdonald RL. Grading of subarachnoid hemorrhage: modification of  
379 the world World Federation of Neurosurgical Societies scale on the basis of data  
380 for a large series of patients. *Neurosurgery*. 2004;54(3):566-575; discussion 575-  
381 566.

- 382 29. Salary M, Quigley MR, Wilberger JE, Jr. Relation among aneurysm size, amount of  
 383 subarachnoid blood, and clinical outcome. *Journal of neurosurgery*.  
 384 2007;107(1):13-17.
- 385 30. de Toledo P, Rios PM, Ledezma A, Sanchis A, Alen JF, Lagares A. Predicting the  
 386 outcome of patients with subarachnoid hemorrhage using machine learning  
 387 techniques. *IEEE Trans Inf Technol Biomed*. 2009;13(5):794-801.
- 388 31. Lo BW, Fukuda H, Angle M, et al. Aneurysmal subarachnoid hemorrhage  
 389 prognostic decision-making algorithm using classification and regression tree  
 390 analysis. *Surgical neurology international*. 2016;7:73.
- 391 32. Turck N, Vutskits L, Sanchez-Pena P, et al. A multiparameter panel method for  
 392 outcome prediction following aneurysmal subarachnoid hemorrhage. *Intensive*  
 393 *care medicine*. 2010;36(1):107-115.
- 394 33. Simundic AM. Measures of Diagnostic Accuracy: Basic Definitions. *EJIFCC*.  
 395 2009;19(4):203-211.
- 396 34. Harrell FE. *Regression modeling strategies: with applications to linear models,*  
 397 *logistic regression, and survival analysis*. Springer-Verlag New York: Springer  
 398 Science & Business Media; 1996.
- 399 35. Dengler NF, Diesing D, Sarrafzadeh A, Wolf S, Vajkoczy P. The Barrow Neurological  
 400 Institute Scale Revisited: Predictive Capabilities for Cerebral Infarction and  
 401 Clinical Outcome in Patients With Aneurysmal Subarachnoid Hemorrhage.  
 402 *Neurosurgery*. 2017;81(2):341-349.
- 403 36. Jaja BNR, Saposnik G, Lingsma HF, et al. Development and validation of outcome  
 404 prediction models for aneurysmal subarachnoid haemorrhage: the SAHIT  
 405 multinational cohort study. *BMJ*. 2018;360:j5745.
- 406 37. Hijdra A, Brouwers PJ, Vermeulen M, van Gijn J. Grading the amount of blood on  
 407 computed tomograms after subarachnoid hemorrhage. *Stroke; a journal of*  
 408 *cerebral circulation*. 1990;21(8):1156-1161.
- 409 38. Jabbarli R, Bohrer AM, Pierscianek D, et al. The CHES score: a simple tool for early  
 410 prediction of shunt dependency after aneurysmal subarachnoid hemorrhage.  
 411 *European journal of neurology*. 2016;23(5):912-918.
- 412 39. Lee VH, Ouyang B, John S, et al. Risk stratification for the in-hospital mortality in  
 413 subarachnoid hemorrhage: the HAIR score. *Neurocritical care*. 2014;21(1):14-19.
- 414 40. Naval NS, Kowalski RG, Chang TR, Caserta F, Carhuapoma JR, Tamargo RJ. The SAH  
 415 Score: a comprehensive communication tool. *Journal of stroke and cerebrovascular*  
 416 *diseases : the official journal of National Stroke Association*. 2014;23(5):902-909.
- 417 41. Szklener S, Melges A, Korchut A, et al. Predictive model for patients with poor-  
 418 grade subarachnoid haemorrhage in 30-day observation: a 9-year cohort study.  
 419 *BMJ open*. 2015;5(6):e007795.
- 420 42. van Donkelaar CE, Bakker NA, Veeger NJ, et al. Prediction of outcome after  
 421 subarachnoid hemorrhage: timing of clinical assessment. *Journal of neurosurgery*.  
 422 2017;126(1):52-59.
- 423 43. Schatlo B, Fung C, Fathi AR, et al. Introducing a nationwide registry: the Swiss study  
 424 on aneurysmal subarachnoid haemorrhage (Swiss SOS). *Acta neurochirurgica*.  
 425 2012;154(12):2173-2178; discussion 2178.
- 426
- 427
- 428

## 429 FIGURE LEGEND

430 Figure 1) AUC for prediction of CVS by Fisher grade according to Wilson et al.,  
431 Figure 2A) AUC for prediction of CVS by age, sex BNI score, and hypertension, 2B) AUC for  
432 prediction of DCI by age, sex BNI score, and hypertension, 2C) AUC for prediction of  
433 infarction by age, BNI score, WNFS, DCI and hypertension  
434 Figure 3A) AUC for prediction of DCI by BNI score sub-stratified by Fisher grade 3 according  
435 to Neidert et al,3B) AUC for prediction of unfavorable outcome by BNI score sub-stratified by  
436 Fisher grade 3, 3C) AUC for prediction of unfavorable outcome by BNI score, WFNS score  
437 and dichotomize age (below and above 60 years) sub-stratified by Fisher grade 3.  
438 Figure 4) AUC for prediction of unfavorable outcome by BNI score, rebleeding, age, clipping,  
439 WNFS, and hydrocephalus  
440 Figure 5) AUC for prediction of unfavorable outcome using the HATCH score in the validation  
441 dataset

442

#### 443 **SUPPLEMENTARY DATA LEGEND**

444 Supplemental Figure 1, Flowchart

445 Supplemental Figure 2, GOS distribution by BNI score

446 Supplemental Figure 3, Graph demonstrating the HATCH score vs risk of unfavorable outcome

447 Supplemental Tables 1-7, 1) Univariable analysis for outcome CVS, 2) Univariable analysis for

448 outcome DCI, 3) Univariable analysis for outcome cerebral infarction, 4) Univariable analysis

449 for outcome unfavorable outcome, 5) Multivariable model for creation of a risk score for

450 prediction of CVS, 6) Multivariable model for creation of a risk score for prediction of DCI, 7)

451 Multivariable model for creation of a risk score for prediction of cerebral infarct

452

453